Novel molecules display potent and selective action against ovarian tumour cells

Google+ Pinterest LinkedIn Tumblr +

A group led by a researcher affiliated with the University of São Paulo’s São Carlos Chemistry Institute (IQSC-USP) in Brazil has developed a novel palladium compound that acts against ovarian tumour cells without affecting healthy tissues.

Palladium is a silvery white metal belonging to the same group as platinum.

The molecule acts more selectively and powerfully in vitro than cisplatin, a platinum-based chemotherapy medication that is used to treat several types of cancer (such as testicular, bladder and head and neck cancer).

This new compound also has the advantage of being effective against ovarian tumours that are resistant to cisplatin.

An article describing the study and signed by researchers from Brazil, the United Kingdom and Italy has been published in Dalton Transactions and is featured on the cover of the journal.

“Cisplatin is a highly effective chemo drug for this kind of tumour, which is typically very aggressive and needs to be combated rapidly.

However, it can have severe side effects, especially on the kidneys, nervous system and hearing. This is because the molecule isn’t very selective, so it also affects healthy cells,” said Victor Marcelo Deflon, a professor at IQSC-USP and principal investigator for the project.

More stable

As the researchers explained, palladium compounds are quickly metabolised in humans, hindering their penetration into tumour cells and preventing them from reaching their molecular target.

Therefore, to make their use in cancer treatment feasible, it was necessary to develop molecules capable of forming more stable palladium species.

The group produced several platinum- and palladium-based complexes.

After testing the various combinations, the scientists identified two that contained compounds called thiosemicarbazones, a class of ligands that promote stabilisation.

The chemical structures of the compounds were characterised by X-ray diffraction, a technique in which X-rays directed toward a sample produce a diffraction pattern that is used to analyse the material’s structure.

Some thiosemicarbazones are known to act on topoisomerases, enzymes that are present in tumours and participate in DNA replication, making them a potential target for chemotherapy drugs.

Cisplatin acts directly on DNA, changing its structure in ways that prevent tumour cells from copying it.

“They’re different targets, but both cisplatin and these palladium compounds inhibit tumour cell division,” Deflon explained.

Effect on the cell nucleus

Complex 1, named as such by the researchers because they considered it the most promising combination of palladium and thiosemicarbazone, acts directly on topoisomerase.

Tests performed by the group using cultured tumour cells showed that 70% of the complex crossed the tumour cell membrane within 24 hours.

Most of it was deposited in the cytoskeleton, a network of interlinking protein filaments present in the cytoplasm of all cells.

A small proportion (approximately 3%) entered the nucleus.

An even smaller proportion of platinum manages to reach the nucleus from the platinum-containing compounds currently in use.

The action of Complex 1 was twice as potent against tumour cells normally resistant to cisplatin.

Moreover, it did not affect healthy cells.

This selectivity should make it less toxic and avoid the side effects of current treatments.

Complex 2 is more selective than cisplatin, but its action is more effective only against a variety of tumour cells that are also sensitive to cisplatin, suggesting that its action mechanism may be the same as that of cisplatin.

More experiments will have to be performed to refute this hypothesis.

Furthermore, only 18% of the complex is able to cross the tumour cell membrane.

The researchers are now working on a project to develop even more effective versions of Complex 1.

The idea is to obtain a molecule that can be tested in animal models with a better chance of success.

Only after successful tests in these models will it be possible to begin clinical trials.

Source: Fundação de Amparo à Pesquisa do Estado de São Paulo


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.